Annovis Bio Inc (NYSE: ANVS) — Company Overview, News & Financial Data
Annovis Bio develops therapies for neurodegenerative disorders like Alzheimer's, focusing on halting disease progression.
Annovis Bio Inc
Annovis Bio (NYSEAMERICAN:ANVS) specializes in developing novel therapies aimed at treating neurodegenerative disorders such as Alzheimer’s and Parkinson’s disease. This pioneering venture focuses on addressing the underlying causes of these debilitating conditions, striving to halt or reverse the progression of symptoms. Annovis Bio’s projects are centered on its innovative lead compound, aiming to improve cognitive and motor functions in affected individuals. Through rigorous research and development, the company’s objective is to offer groundbreaking treatments that can significantly enhance the quality of life for patients grappling with these challenging disorders, marking a substantial step forward in neurodegenerative disease management.
Snapshot
Operations
Products and/or services of Annovis Bio Inc
- Development of ANVS401 for neurodegenerative diseases, focusing on Alzheimer's and Parkinson's.
- Research into bispecific antibody technology for targeting neurodegenerative disease pathways.
- Investigation of ANVS405 for the protection of nerve cells in neurodegenerative conditions.
- Exploration of treatments aimed at reducing neuroinflammation as a common symptom of neurodegenerative diseases.
- Involvement in early-stage discovery of biomarkers for neurodegenerative diseases to improve diagnosis and treatment.
- Contribution to a collaborative project focused on understanding the role of toxic proteins in the progression of neurodegenerative diseases.
Annovis Bio Inc executive team
- Maria L. MaccecchiniFounder, Acting CFO, CEO, President & Executive Director
- Cheng FangChief Scientific Officer
- Eve M. DamianoSenior Vice President of Regulatory Operations
- Blake JensenHead of Quality
- Hilda MaibachSenior Vice President of Statistics
Latest news about Annovis Bio Inc
Key financials
Reported results for Annovis Bio Inc, in USD.
- Market cap
- 43.5M
- Revenue (TTM)
- 0
- P/E ratio
- —
- EPS (diluted, TTM)
- -1.8
- Dividend yield
- —
- Profit margin
- 0.0%
| Fiscal year end | Revenue | Operating income | Net income |
|---|---|---|---|
| 0 | -29.7M | -28.9M | |
| 0 | -26.7M | -24.6M | |
| 0 | -45M | -56.2M | |
| 0 | -25.5M | -25.1M |